These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38140900)

  • 1. Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.
    Merker VL; Thompson HL; Wolters PL; Buono FD; Hingtgen CM; Rosser T; Barton B; Barnett C; Smith T; Haberkamp D; McManus ML; Baldwin A; Moss IP; Röhl C; Martin S
    Clin Trials; 2024 Feb; 21(1):6-17. PubMed ID: 38140900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.
    Thompson HL; Grabowski J; Franklin B; Koetsier KS; Welling DB
    Clin Trials; 2024 Feb; 21(1):18-28. PubMed ID: 38321701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using a qualitative approach to conceptualize concerns of patients with neurofibromatosis type 1 associated plexiform neurofibromas (pNF) across the lifespan.
    Lai JS; Jensen SE; Patel ZS; Listernick R; Charrow J
    Am J Med Genet A; 2017 Jan; 173(1):79-87. PubMed ID: 27666129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials.
    Wolters PL; Vranceanu AM; Thompson HL; Martin S; Merker VL; Baldwin A; Barnett C; Koetsier KS; Hingtgen CM; Funes CJ; Tonsgard JH; Schorry EK; Allen T; Smith T; Franklin B; Reeve S;
    Neurology; 2021 Aug; 97(7 Suppl 1):S50-S63. PubMed ID: 34230198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Systematic Review of Recent and Ongoing Clinical Trials in Patients With the Neurofibromatoses.
    Acar S; Nieblas-Bedolla E; Armstrong AE; Hirbe AC
    Pediatr Neurol; 2022 Sep; 134():1-6. PubMed ID: 35759947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging Evaluation of Plexiform Neurofibromas in Neurofibromatosis Type 1: A Survey-Based Assessment.
    Ahlawat S; Ly KI; Fayad LM; Fisher MJ; Lessing AJ; Berg DJ; Salamon JM; Mautner VF; Babovic-Vuksanovic D; Dombi E; Harris G; Plotkin SR; Blakeley J;
    Neurology; 2021 Aug; 97(7 Suppl 1):S111-S119. PubMed ID: 34230200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and pilot validation of a novel disfigurement severity scale for plexiform neurofibromas in children with neurofibromatosis type 1.
    John L; Singh G; Dombi E; Wolters PL; Martin S; Baldwin A; Steinberg SM; Bernstein J; Whitcomb P; Pichard DC; Dufek A; Gillespie A; Heisey K; Bornhorst M; Fisher MJ; Weiss BD; Kim A; Widemann BC; Gross AM
    Clin Trials; 2024 Apr; 21(2):189-198. PubMed ID: 37877369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selumetinib in Children with Inoperable Plexiform Neurofibromas.
    Gross AM; Wolters PL; Dombi E; Baldwin A; Whitcomb P; Fisher MJ; Weiss B; Kim A; Bornhorst M; Shah AC; Martin S; Roderick MC; Pichard DC; Carbonell A; Paul SM; Therrien J; Kapustina O; Heisey K; Clapp DW; Zhang C; Peer CJ; Figg WD; Smith M; Glod J; Blakeley JO; Steinberg SM; Venzon DJ; Doyle LA; Widemann BC
    N Engl J Med; 2020 Apr; 382(15):1430-1442. PubMed ID: 32187457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient Reported Outcomes Measurement Information System and Quality of Life in Neurological Disorders Measurement System to Evaluate Quality of Life for Children and Adolescents with Neurofibromatosis Type 1 Associated Plexiform Neurofibroma.
    Lai JS; Jensen SE; Charrow J; Listernick R
    J Pediatr; 2019 Mar; 206():190-196. PubMed ID: 30413310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas: Implications for Clinical Trials.
    Cannon A; Pichard DC; Wolters PL; Adsit S; Erickson G; Lessing AJ; Li P; Narmore W; Röhl C; Rosser T; Widemann BC; Blakeley JO; Plotkin SR;
    Neurology; 2021 Aug; 97(7 Suppl 1):S15-S24. PubMed ID: 34230202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials.
    Wolters PL; Martin S; Merker VL; Gardner KL; Hingtgen CM; Tonsgard JH; Schorry EK; Baldwin A;
    Neurology; 2013 Nov; 81(21 Suppl 1):S6-14. PubMed ID: 24249806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.
    Dhaenens BAE; van Dijk SA; Taal W; Noordhoek DC; Coffey A; McKenna SP; Oostenbrink R
    J Patient Rep Outcomes; 2024 Mar; 8(1):33. PubMed ID: 38499890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recommendations for imaging tumor response in neurofibromatosis clinical trials.
    Dombi E; Ardern-Holmes SL; Babovic-Vuksanovic D; Barker FG; Connor S; Evans DG; Fisher MJ; Goutagny S; Harris GJ; Jaramillo D; Karajannis MA; Korf BR; Mautner V; Plotkin SR; Poussaint TY; Robertson K; Shih CS; Widemann BC;
    Neurology; 2013 Nov; 81(21 Suppl 1):S33-40. PubMed ID: 24249804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials.
    Wolters PL; Martin S; Merker VL; Tonsgard JH; Solomon SE; Baldwin A; Bergner AL; Walsh K; Thompson HL; Gardner KL; Hingtgen CM; Schorry E; Dudley WN; Franklin B;
    Neurology; 2016 Aug; 87(7 Suppl 1):S4-S12. PubMed ID: 27527648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Giant gluteal and vesical plexiform neurofibromas in a patient with neurofibromatosis type 1: a case report.
    Sassi I; Bouida MA; Hasnaoui A; Zemni I; Ben Dhieb T
    J Med Case Rep; 2024 Jan; 18(1):15. PubMed ID: 38216958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.
    Heaney A; Wilburn J; Rouse M; Langmead S; Blakeley JO; Huson S; McKenna SP
    Mol Genet Genomic Med; 2020 Dec; 8(12):e1530. PubMed ID: 33085177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is a plexiform neurofibroma pathognomonic of neurofibromatosis type I?
    Lin V; Daniel S; Forte V
    Laryngoscope; 2004 Aug; 114(8):1410-4. PubMed ID: 15280718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Central and Peripheral Nervous System Tumors in Patients with Neurofibromatosis.
    Brown R
    Curr Oncol Rep; 2023 Dec; 25(12):1409-1417. PubMed ID: 37906356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Miniature Palpebral Plexiform Neurofibroma in Neurofibromatosis Type 2.
    Charles NC; Kim ET
    Ophthalmic Plast Reconstr Surg; 2023 Nov-Dec 01; 39(6):e186-e188. PubMed ID: 37338324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.